Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Corn

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
Cancer Research|November 5, 2015
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate CancerYu-Chen Lee, Song-Chang Lin, Guoyu Yu, et al.
Molecular Cancer Research : MCR|August 31, 2021
Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate CancerShoujie Chai, Nicholas Matsumoto, Ryan Storgard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate CancerPaymaneh D Malihi, Ryon P Graf, Angel Rodriguez, et al.
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
Cancer Medicine|March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone MicroenvironmentIoulia Vardaki, Paul Corn, Emanuela Gentile, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
Clinical and Translational Radiation Oncology|August 27, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer centerAlan J Sosa, Michael K Rooney, Howard D Thames, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
Cancer Research|November 5, 2015
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate CancerYu-Chen Lee, Song-Chang Lin, Guoyu Yu, et al.
Molecular Cancer Research : MCR|August 31, 2021
Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate CancerShoujie Chai, Nicholas Matsumoto, Ryan Storgard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate CancerPaymaneh D Malihi, Ryon P Graf, Angel Rodriguez, et al.
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
Cancer Medicine|March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone MicroenvironmentIoulia Vardaki, Paul Corn, Emanuela Gentile, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
Clinical and Translational Radiation Oncology|August 27, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer centerAlan J Sosa, Michael K Rooney, Howard D Thames, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Pageof 4